Mizuho analyst Steven Valiquette initiated coverage of Teladoc (TDOC) with a Neutral rating and $10 price target The firm is encouraged by Teladoc’s growth in its Integrated Care segment but is concerned about the potential pace of BetterHelp attrition over the near term. The company’s customer acquisition costs remain elevated, and consumer sentiment remains well below historical averages in 2025, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Mixed Prospects: Hold Rating Amid Growth in Integrated Care and Challenges in BetterHelp Segment
- Options Volatility and Implied Earnings Moves Today, July 24, 2025
- Teladoc Secures $300M Credit Facility with JPMorgan
- Teladoc’s Mixed Performance: Hold Rating Amid Declining BetterHelp MAUs and Livongo’s Recovery
- OpenEvidence Is Quietly Becoming the Google of Medicine